

## Imbruvica (Tablet) - (140,560 mg; Tablet)

|                              |   |                             |                     |
|------------------------------|---|-----------------------------|---------------------|
| <b>Generic Name</b>          | IBRUTINIB   | <b>Innovator</b>            | Pharmacyclics       |
| <b>Dosage</b>                | 140,560 mg; Tablet  | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5   | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | More Than 5   | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None  | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | Used to treat certain cancers (such as mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia) |                             |                     |
| <b>Complexities</b>          | Yes   |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Imbruvica (Tablet) - (280,420 mg; Tablet, Oral)

|                              |  |                             |                     |
|------------------------------|--|-----------------------------|---------------------|
| <b>Generic Name</b>          | IBRUTINIB  | <b>Innovator</b>            | Pharmacyclics       |
| <b>Dosage</b>                | 280,420 mg; Tablet, Oral   | <b>Branded US Sales</b>     | More Than \$1000 mn |
| <b>Probable FTF</b>          | Less Than 5  | <b>Known Para IV Filers</b> | Less Than 5         |
| <b>Other ANDA developers</b> | More Than 5  | <b>Tentative Approvals</b>  | Less Than 5         |
| <b>Final Approvals</b>       | None   | <b>Generic Launches</b>     | None                |
| <b>Indication</b>            | IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with: Mantle cell lymphoma (MCL) who have received at least one prior treatment. Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion. |                             |                     |
| <b>Complexities</b>          | Yes  |                             |                     |

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.